Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Horizon Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® Concomitantly Used with the Immunomodulator Mycophenolate Mofetil

Contact the Supplier

Lead Product(s): Pegloticase,Mycophenolate Mofetil

Therapeutic Area: Musculoskeletal Product Name: Krystexxa

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2020

Details:

Reducing Immunogenicity of Pegloticase demonstrated that 86.4 percent of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL through Month 3, the primary endpoint of the study.

Horizon Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

New Data Evaluating KRYSTEXXA® With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020

Contact the Supplier

Lead Product(s): Pegloticase,Mycophenolate Mofetil

Therapeutic Area: Musculoskeletal Product Name: Krystexxa

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 08, 2020

Details:

Additional studies on the concomitant use of KRYSTEXXA (pegloticase injection) with an immunomodulator to optimize the treatment for people living with chronic gout refractory to conventional therapies (also known as uncontrolled gout) will also be presented.